A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions
Trachoma
Interventions
OTHER

Surveillance and treatment with azithromycin of newcomer and traveler families

The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration

OTHER

Usual care

Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.

Trial Locations (1)

21205

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

National Eye Institute (NEI)

NIH

lead

Johns Hopkins University

OTHER

NCT01767506 - A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial | Biotech Hunter | Biotech Hunter